These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32080995)

  • 1. Asprosin and type 2 diabetes mellitus: a novel potential therapeutic implication.
    Bhadel P; Shrestha S; Sapkota B; Li JY; Tao H
    J Biol Regul Homeost Agents; 2020 Feb; 34(1):. PubMed ID: 32080995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asprosin, a novel glucogenic adipokine implicated in type 2 diabetes mellitus.
    Diao H; Li X; Xu Y; Xing X; Pang S
    J Diabetes Complications; 2023 Nov; 37(11):108614. PubMed ID: 37769508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the
    Ovali MA; Bozgeyik I
    Mol Syndromol; 2022 May; 13(3):175-183. PubMed ID: 35707591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence.
    Shabir K; Brown JE; Afzal I; Gharanei S; Weickert MO; Barber TM; Kyrou I; Randeva HS
    Cytokine Growth Factor Rev; 2021 Aug; 60():120-132. PubMed ID: 34108103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.
    Dai C; Zhu W
    Medicine (Baltimore); 2022 Oct; 101(43):e31334. PubMed ID: 36316938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asprosin-A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature.
    Mazur-Bialy AI
    Nutrients; 2021 Feb; 13(2):. PubMed ID: 33673009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects.
    Farrag M; Ait Eldjoudi D; González-Rodríguez M; Cordero-Barreal A; Ruiz-Fernández C; Capuozzo M; González-Gay MA; Mera A; Lago F; Soffar A; Essawy A; Pino J; Farrag Y; Gualillo O
    Front Endocrinol (Lausanne); 2022; 13():1101091. PubMed ID: 36686442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asprosin: A Novel Player in Metabolic Diseases.
    Yuan M; Li W; Zhu Y; Yu B; Wu J
    Front Endocrinol (Lausanne); 2020; 11():64. PubMed ID: 32153505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrillin-1 and asprosin, novel players in metabolic syndrome.
    Summers KM; Bush SJ; Davis MR; Hume DA; Keshvari S; West JA
    Mol Genet Metab; 2023 Jan; 138(1):106979. PubMed ID: 36630758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride.
    Zhang L; Chen C; Zhou N; Fu Y; Cheng X
    Clin Chim Acta; 2019 Feb; 489():183-188. PubMed ID: 29104036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy.
    Goodarzi G; Setayesh L; Fadaei R; Khamseh ME; Aliakbari F; Hosseini J; Moradi N
    Mol Biol Rep; 2021 Jul; 48(7):5443-5450. PubMed ID: 34304366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin.
    Gozel N; Kilinc F
    Endokrynol Pol; 2021; 72(1):37-43. PubMed ID: 32944923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effects of Asprosin on Exercise-Intervention in Metabolic Diseases.
    Liu L; Liu Y; Huang M; Zhang M; Zhu C; Chen X; Bennett S; Xu J; Zou J
    Front Physiol; 2022; 13():907358. PubMed ID: 35899030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases.
    Li X; Liao M; Shen R; Zhang L; Hu H; Wu J; Wang X; Qu H; Guo S; Long M; Zheng H
    Mediators Inflamm; 2018; 2018():7375294. PubMed ID: 30524197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of asprosin and Nrg-4 with type 2 diabetes Mellitus Complicated with Coronary Heart Disease and the Diagnostic Value.
    Zhong M; Tian X; Sun Q; Li L; Lu Y; Feng Z; Gao Y; Li S
    BMC Endocr Disord; 2023 Mar; 23(1):61. PubMed ID: 36915073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrillin-1 and fibrillin-1-derived asprosin in adipose tissue function and metabolic disorders.
    Muthu ML; Reinhardt DP
    J Cell Commun Signal; 2020 Jun; 14(2):159-173. PubMed ID: 32279186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asprosin is a centrally acting orexigenic hormone.
    Duerrschmid C; He Y; Wang C; Li C; Bournat JC; Romere C; Saha PK; Lee ME; Phillips KJ; Jain M; Jia P; Zhao Z; Farias M; Wu Q; Milewicz DM; Sutton VR; Moore DD; Butte NF; Krashes MJ; Xu Y; Chopra AR
    Nat Med; 2017 Dec; 23(12):1444-1453. PubMed ID: 29106398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Energy Regulation Mechanism and Therapeutic Potential of Asprosin.
    Hoffmann JG; Xie W; Chopra AR
    Diabetes; 2020 Apr; 69(4):559-566. PubMed ID: 32198197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus.
    Zhang X; Jiang H; Ma X; Wu H
    J Diabetes Investig; 2020 Mar; 11(2):349-355. PubMed ID: 31529619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the new adipokine asprosin be a metabolic troublemaker for cardiovascular diseases? A state-of-the-art review.
    Zhang Z; Zhu L; Wang Z; Hua N; Hu S; Chen Y
    Prog Lipid Res; 2023 Jul; 91():101240. PubMed ID: 37473965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.